| 5 | Efficacy and safety of onabotulinum toxin A for overactive bladder显示文摘Overactive bladder(OAB) syndrome is a condition which affects 16.9% of women and 16.2% of men with a significant negative impact on quality of life. It is a condition characterized by urgency, with or without urge incontinence, frequency and nocturia. Behavioral modifications and oral anti-muscurinic medications are first and second-line therapies for OAB but are frequently ineffective or poorly tolerated. For refractory cases of OAB, onabotulinum toxin can be offered and this therapy was approved by the Food and Drug Administration in January of 2013. In this editorial, we will review the indications, usage, efficacy and safety data for intradetrusor injection of onabotulinum toxin A. | Chintan K Patel Arthur P Mourtzinos | 2016 | World Journal of Clinical Urology2016，5，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员